Oligonucleotide CDMO Market worth $11.14 billion by 2031 - Exclusive Report by MarketsandMarkets™

MarketsandMarkets projects the global oligonucleotide CDMO market to grow from $3.88B in 2026 to $11.14B by 2031, implying a 23.5% CAGR. North America is expected to remain the largest region (43.2% share in 2025), with contract manufacturing the biggest service segment (42.1%) and therapeutic applications leading (largest share in 2025). The report also cites notable capacity/investment moves—e.g., Agilent’s commitment of more than $740M since 2023 to scale commercial oligonucleotide manufacturing—and highlights acquisitions such as Agilent’s $925M BIOVECTRA deal (completed Sept 2024) to expand RNA therapeutics and gene-editing capabilities.

Analysis

The actionable signal is not the market-size forecast itself; it is the industry preference for integrated, validated manufacturing plus analytics. That tends to reward incumbents with installed GMP capacity and sticky development relationships, because once a program clears the clinic, switching costs and regulatory friction become meaningful barriers. In the next 1-3 months, the key economic read-through is utilization and mix, not headline top-line growth.

Among the listed names, A has the cleanest operating leverage to this theme because its recent capacity expansion can convert into higher-margin throughput if demand is real. TMO should benefit at the margin through broader outsourcing and analytical demand, but the theme is too small relative to its diversified base to justify a large fundamental re-rating on this news alone. WUXAY can still win share, but any multiple expansion is likely capped by geopolitical and policy risk that keeps foreign capital cautious even if end-market growth is intact.

The contrarian risk is that investors are treating a forecast like contracted revenue: if new capacity outruns actual oligo demand, pricing can compress and the P&L benefit shifts from growth to utilization discipline. That would hit smaller or less integrated providers first, while the winners are the platforms with the strongest development-to-commercial handoff. Falsify the bullish read-through by looking for flat backlog, lower-than-expected capacity utilization, or management commentary that 2027-2028 line activations are being pushed out.

Key Decisions for Investors

• Long A on weakness over the next 1-3 months; thesis is that oligo/CDMO demand supports incremental utilization and margin mix. Risk/reward is favorable if management confirms backlog conversion; cut if CDMO growth commentary stalls or gross margin fails to inflect.
• Pair trade: long A / short TMO for 1-3 months as a relative-value expression on direct exposure versus diversified exposure. This works only if the market starts paying for oligo-specific optionality; cover the short if broader life-science tools rerate on a cyclical recovery.
• Underweight or hedge WUXAY rather than chasing the growth story; the structural discount from geopolitical risk can dominate any sector tailwind over 6-18 months. Reassess only if there is evidence of durable contract wins without incremental policy headlines.